# HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

> **NCT05740813** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merit E. Cudkowicz, MD** · enrollment: 310 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ABBV-CLS-7262 Dose 1
- **DRUG:** ABBV-CLS-7262 Dose 2
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT05740813
- **Lead sponsor:** Merit E. Cudkowicz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-23
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-10-03
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740813, "HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05740813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*